Trabecular reorganization in consecutive iliac crest biopsies when switching from bisphosphonate to strontium ranelate treatment.
Standard
Trabecular reorganization in consecutive iliac crest biopsies when switching from bisphosphonate to strontium ranelate treatment. / Jobke, Björn; Burghardt, Andrew J; Muche, Burkhard; Hahn, Michael; Semler, Jutta; Amling, Michael; Majumdar, Sharmila; Busse, Björn.
In: PLOS ONE, Vol. 6, No. 8, 8, 2011, p. 23638.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Trabecular reorganization in consecutive iliac crest biopsies when switching from bisphosphonate to strontium ranelate treatment.
AU - Jobke, Björn
AU - Burghardt, Andrew J
AU - Muche, Burkhard
AU - Hahn, Michael
AU - Semler, Jutta
AU - Amling, Michael
AU - Majumdar, Sharmila
AU - Busse, Björn
PY - 2011
Y1 - 2011
N2 - Several agents are available to treat osteoporosis while addressing patient-specific medical needs. Individuals' residual risk to severe fracture may require changes in treatment strategy. Data at osseous cellular and microstructural levels due to a therapy switch between agents with different modes of action are rare. Our study on a series of five consecutively taken bone biopsies from an osteoporotic individual over a six-year period analyzes changes in cellular characteristics, bone microstructure and mineralization caused by a therapy switch from an antiresorptive (bisphosphonate) to a dual action bone agent (strontium ranelate).
AB - Several agents are available to treat osteoporosis while addressing patient-specific medical needs. Individuals' residual risk to severe fracture may require changes in treatment strategy. Data at osseous cellular and microstructural levels due to a therapy switch between agents with different modes of action are rare. Our study on a series of five consecutively taken bone biopsies from an osteoporotic individual over a six-year period analyzes changes in cellular characteristics, bone microstructure and mineralization caused by a therapy switch from an antiresorptive (bisphosphonate) to a dual action bone agent (strontium ranelate).
KW - Biopsy
KW - Humans
KW - Aged
KW - Female
KW - Treatment Outcome
KW - Time Factors
KW - X-Ray Microtomography
KW - Absorptiometry, Photon
KW - Bone Density/drug effects
KW - Bone Density Conservation Agents/therapeutic use
KW - Bone and Bones/drug effects/metabolism/pathology
KW - Diphosphonates/therapeutic use
KW - Ilium/drug effects/metabolism/pathology
KW - Organometallic Compounds/therapeutic use
KW - Osteoporosis, Postmenopausal/complications/drug therapy/pathology
KW - Spinal Fractures/drug therapy/etiology
KW - Thiophenes/therapeutic use
KW - Biopsy
KW - Humans
KW - Aged
KW - Female
KW - Treatment Outcome
KW - Time Factors
KW - X-Ray Microtomography
KW - Absorptiometry, Photon
KW - Bone Density/drug effects
KW - Bone Density Conservation Agents/therapeutic use
KW - Bone and Bones/drug effects/metabolism/pathology
KW - Diphosphonates/therapeutic use
KW - Ilium/drug effects/metabolism/pathology
KW - Organometallic Compounds/therapeutic use
KW - Osteoporosis, Postmenopausal/complications/drug therapy/pathology
KW - Spinal Fractures/drug therapy/etiology
KW - Thiophenes/therapeutic use
U2 - 10.1371/journal.pone.0023638
DO - 10.1371/journal.pone.0023638
M3 - SCORING: Journal article
VL - 6
SP - 23638
JO - PLOS ONE
JF - PLOS ONE
SN - 1932-6203
IS - 8
M1 - 8
ER -
